{ "title": "Peptide Local Australia Compound-by-State and Territory Verification Atlas", "identifier": "https://peptidelocal.com/data/australia-peptide-state-index#dataset", "version": "2026-07-20", "scope": "Compound identity, ARTG product records, practitioner checks, and Australian state and territory pharmacy or medicines routes. Rows are not blanket legal, availability, safety, quality, medical, or seller determinations.", "methodology": "https://peptidelocal.com/methodology", "dictionary": { "recordId": "Stable Peptide Local identifier for one compound and Australian state or territory verification row.", "compound": "Resolved research-market, clinical-pipeline, or medicine identity used by the linked evidence record.", "evidenceLane": "The evidence category for the resolved identity. Research listings, clinical programs, and medicine records are not interchangeable.", "jurisdiction": "Destination Australian state or territory whose official pharmacy, premises, or medicines route is linked.", "searchQuery": "Plain-language compound and jurisdiction query represented by this row.", "boundedAnswer": "Editorial routing answer stating what the identity, ARTG record, practitioner record, and local route can and cannot establish.", "identitySourceUrl": "Primary source for the compound, medicine, or clinical-program identity.", "jurisdictionRecordUrl": "Official state or territory pharmacy, premises, medicines, licence, or registration route.", "productRecordUrl": "TGA route used for the separate Australian Register of Therapeutic Goods check.", "canonicalAtlasUrl": "Canonical Peptide Local atlas section for the exact compound and jurisdiction row.", "reviewedDate": "ISO date when the compound and Australian jurisdiction source route was reviewed." }, "records": [ { "recordId": "pl-australia-region-kpv-australian-capital-territory", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "KPV in Australian Capital Territory", "boundedAnswer": "KPV in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-new-south-wales", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "KPV in New South Wales", "boundedAnswer": "KPV in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-northern-territory-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "KPV in Northern Territory", "boundedAnswer": "KPV in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-queensland-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "KPV in Queensland", "boundedAnswer": "KPV in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-south-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "KPV in South Australia", "boundedAnswer": "KPV in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-tasmania-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "KPV in Tasmania", "boundedAnswer": "KPV in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-victoria-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "KPV in Victoria", "boundedAnswer": "KPV in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-kpv-western-australia", "compound": "KPV", "compoundSlug": "kpv", "compoundAliases": [ "Lys-Pro-Val", "lysine-proline-valine", "MSH 11-13", "alpha-MSH 11-13", "KPV peptide" ], "evidenceLane": "FDA-reviewed unapproved peptide identity", "identityStatus": "FDA-reviewed unapproved peptide identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "KPV in Western Australia", "boundedAnswer": "KPV in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/guides/kpv-peptide-benefits-safety-fda-status", "identitySourceLabel": "FDA briefing document for KPV-related bulk drug substances", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/media/193346/download", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kpv/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kpv/countries" }, { "recordId": "pl-australia-region-bpc-157-australian-capital-territory", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "BPC-157 in Australian Capital Territory", "boundedAnswer": "BPC-157 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-new-south-wales", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "BPC-157 in New South Wales", "boundedAnswer": "BPC-157 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-northern-territory-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "BPC-157 in Northern Territory", "boundedAnswer": "BPC-157 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-queensland-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "BPC-157 in Queensland", "boundedAnswer": "BPC-157 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-south-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "BPC-157 in South Australia", "boundedAnswer": "BPC-157 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-tasmania-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "BPC-157 in Tasmania", "boundedAnswer": "BPC-157 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-victoria-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "BPC-157 in Victoria", "boundedAnswer": "BPC-157 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-bpc-157-western-australia", "compound": "BPC-157", "compoundSlug": "bpc-157", "compoundAliases": [ "Body Protection Compound 157", "BPC 157" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "BPC-157 in Western Australia", "boundedAnswer": "BPC-157 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/bpc-157", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/bpc-157/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/bpc-157/countries" }, { "recordId": "pl-australia-region-tb-500-australian-capital-territory", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "TB-500 in Australian Capital Territory", "boundedAnswer": "TB-500 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-new-south-wales", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "TB-500 in New South Wales", "boundedAnswer": "TB-500 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-northern-territory-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "TB-500 in Northern Territory", "boundedAnswer": "TB-500 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-queensland-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "TB-500 in Queensland", "boundedAnswer": "TB-500 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-south-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "TB-500 in South Australia", "boundedAnswer": "TB-500 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-tasmania-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "TB-500 in Tasmania", "boundedAnswer": "TB-500 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-victoria-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "TB-500 in Victoria", "boundedAnswer": "TB-500 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-tb-500-western-australia", "compound": "TB-500", "compoundSlug": "tb-500", "compoundAliases": [ "Thymosin beta-4 fragment", "TB500" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "TB-500 in Western Australia", "boundedAnswer": "TB-500 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tb-500", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tb-500/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tb-500/countries" }, { "recordId": "pl-australia-region-ghk-cu-australian-capital-territory", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "GHK-Cu in Australian Capital Territory", "boundedAnswer": "GHK-Cu in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-new-south-wales", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "GHK-Cu in New South Wales", "boundedAnswer": "GHK-Cu in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-northern-territory-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "GHK-Cu in Northern Territory", "boundedAnswer": "GHK-Cu in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-queensland-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "GHK-Cu in Queensland", "boundedAnswer": "GHK-Cu in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-south-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "GHK-Cu in South Australia", "boundedAnswer": "GHK-Cu in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-tasmania-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "GHK-Cu in Tasmania", "boundedAnswer": "GHK-Cu in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-victoria-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "GHK-Cu in Victoria", "boundedAnswer": "GHK-Cu in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-ghk-cu-western-australia", "compound": "GHK-Cu", "compoundSlug": "ghk-cu", "compoundAliases": [ "Copper tripeptide", "GHK Cu", "Copper tripeptide-1", "Prezatide copper" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "GHK-Cu in Western Australia", "boundedAnswer": "GHK-Cu in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ghk-cu", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/71587328", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ghk-cu/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ghk-cu/countries" }, { "recordId": "pl-australia-region-semax-australian-capital-territory", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Semax in Australian Capital Territory", "boundedAnswer": "Semax in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-new-south-wales", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Semax in New South Wales", "boundedAnswer": "Semax in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-northern-territory-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Semax in Northern Territory", "boundedAnswer": "Semax in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-queensland-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Semax in Queensland", "boundedAnswer": "Semax in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-south-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Semax in South Australia", "boundedAnswer": "Semax in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-tasmania-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Semax in Tasmania", "boundedAnswer": "Semax in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-victoria-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Semax in Victoria", "boundedAnswer": "Semax in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-semax-western-australia", "compound": "Semax", "compoundSlug": "semax", "compoundAliases": [ "ACTH(4-7)-PGP", "MEHFPGP", "Semax heptapeptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Semax in Western Australia", "boundedAnswer": "Semax in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/semax", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semax/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semax/countries" }, { "recordId": "pl-australia-region-melanotan-ii-australian-capital-territory", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Melanotan II in Australian Capital Territory", "boundedAnswer": "Melanotan II in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-new-south-wales", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Melanotan II in New South Wales", "boundedAnswer": "Melanotan II in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-northern-territory-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Melanotan II in Northern Territory", "boundedAnswer": "Melanotan II in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-queensland-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Melanotan II in Queensland", "boundedAnswer": "Melanotan II in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-south-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Melanotan II in South Australia", "boundedAnswer": "Melanotan II in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-tasmania-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Melanotan II in Tasmania", "boundedAnswer": "Melanotan II in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-victoria-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Melanotan II in Victoria", "boundedAnswer": "Melanotan II in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-melanotan-ii-western-australia", "compound": "Melanotan II", "compoundSlug": "melanotan-ii", "compoundAliases": [ "MT-II", "MT2", "Melanotan 2" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Melanotan II in Western Australia", "boundedAnswer": "Melanotan II in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-ii", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-ii/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-ii/countries" }, { "recordId": "pl-australia-region-mots-c-australian-capital-territory", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "MOTS-c in Australian Capital Territory", "boundedAnswer": "MOTS-c in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-new-south-wales", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "MOTS-c in New South Wales", "boundedAnswer": "MOTS-c in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-northern-territory-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "MOTS-c in Northern Territory", "boundedAnswer": "MOTS-c in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-queensland-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "MOTS-c in Queensland", "boundedAnswer": "MOTS-c in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-south-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "MOTS-c in South Australia", "boundedAnswer": "MOTS-c in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-tasmania-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "MOTS-c in Tasmania", "boundedAnswer": "MOTS-c in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-victoria-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "MOTS-c in Victoria", "boundedAnswer": "MOTS-c in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-mots-c-western-australia", "compound": "MOTS-c", "compoundSlug": "mots-c", "compoundAliases": [ "MOTS c", "Mitochondrial open reading frame peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "MOTS-c in Western Australia", "boundedAnswer": "MOTS-c in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/mots-c", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mots-c/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mots-c/countries" }, { "recordId": "pl-australia-region-tesamorelin-australian-capital-territory", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Tesamorelin in Australian Capital Territory", "boundedAnswer": "Tesamorelin in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-new-south-wales", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Tesamorelin in New South Wales", "boundedAnswer": "Tesamorelin in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-northern-territory-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Tesamorelin in Northern Territory", "boundedAnswer": "Tesamorelin in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-queensland-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Tesamorelin in Queensland", "boundedAnswer": "Tesamorelin in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-south-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Tesamorelin in South Australia", "boundedAnswer": "Tesamorelin in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-tasmania-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Tesamorelin in Tasmania", "boundedAnswer": "Tesamorelin in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-victoria-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Tesamorelin in Victoria", "boundedAnswer": "Tesamorelin in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-tesamorelin-western-australia", "compound": "Tesamorelin", "compoundSlug": "tesamorelin", "compoundAliases": [ "Egrifta", "TH9507" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-licensed medicine record", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Tesamorelin in Western Australia", "boundedAnswer": "Tesamorelin in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/tesamorelin", "identitySourceLabel": "Check the FDA Purple Book product record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://purplebooksearch.fda.gov/index.cfm?blaNo=022505&event=productdetails", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tesamorelin/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tesamorelin/countries" }, { "recordId": "pl-australia-region-aod-9604-australian-capital-territory", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "AOD-9604 in Australian Capital Territory", "boundedAnswer": "AOD-9604 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-new-south-wales", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "AOD-9604 in New South Wales", "boundedAnswer": "AOD-9604 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-northern-territory-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "AOD-9604 in Northern Territory", "boundedAnswer": "AOD-9604 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-queensland-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "AOD-9604 in Queensland", "boundedAnswer": "AOD-9604 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-south-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "AOD-9604 in South Australia", "boundedAnswer": "AOD-9604 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-tasmania-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "AOD-9604 in Tasmania", "boundedAnswer": "AOD-9604 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-victoria-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "AOD-9604 in Victoria", "boundedAnswer": "AOD-9604 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-aod-9604-western-australia", "compound": "AOD-9604", "compoundSlug": "aod-9604", "compoundAliases": [ "AOD 9604", "AOD9604", "Tyr-hGH 177-191" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a failed oral obesity program and no FDA-approved drug", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "AOD-9604 in Western Australia", "boundedAnswer": "AOD-9604 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/aod-9604", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/aod-9604/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/aod-9604/countries" }, { "recordId": "pl-australia-region-ipamorelin-australian-capital-territory", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Ipamorelin in Australian Capital Territory", "boundedAnswer": "Ipamorelin in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-new-south-wales", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Ipamorelin in New South Wales", "boundedAnswer": "Ipamorelin in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-northern-territory-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Ipamorelin in Northern Territory", "boundedAnswer": "Ipamorelin in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-queensland-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Ipamorelin in Queensland", "boundedAnswer": "Ipamorelin in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-south-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Ipamorelin in South Australia", "boundedAnswer": "Ipamorelin in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-tasmania-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Ipamorelin in Tasmania", "boundedAnswer": "Ipamorelin in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-victoria-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Ipamorelin in Victoria", "boundedAnswer": "Ipamorelin in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-ipamorelin-western-australia", "compound": "Ipamorelin", "compoundSlug": "ipamorelin", "compoundAliases": [ "NNC 26-0161", "growth hormone secretagogue" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Ipamorelin in Western Australia", "boundedAnswer": "Ipamorelin in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/ipamorelin", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ipamorelin/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ipamorelin/countries" }, { "recordId": "pl-australia-region-selank-australian-capital-territory", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Selank in Australian Capital Territory", "boundedAnswer": "Selank in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-new-south-wales", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Selank in New South Wales", "boundedAnswer": "Selank in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-northern-territory-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Selank in Northern Territory", "boundedAnswer": "Selank in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-queensland-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Selank in Queensland", "boundedAnswer": "Selank in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-south-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Selank in South Australia", "boundedAnswer": "Selank in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-tasmania-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Selank in Tasmania", "boundedAnswer": "Selank in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-victoria-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Selank in Victoria", "boundedAnswer": "Selank in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-selank-western-australia", "compound": "Selank", "compoundSlug": "selank", "compoundAliases": [ "TP-7", "selank acetate" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Selank in Western Australia", "boundedAnswer": "Selank in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/selank", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/selank/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/selank/countries" }, { "recordId": "pl-australia-region-pt-141-australian-capital-territory", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "PT-141 / Bremelanotide in Australian Capital Territory", "boundedAnswer": "PT-141 / Bremelanotide in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-new-south-wales", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "PT-141 / Bremelanotide in New South Wales", "boundedAnswer": "PT-141 / Bremelanotide in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-northern-territory-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "PT-141 / Bremelanotide in Northern Territory", "boundedAnswer": "PT-141 / Bremelanotide in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-queensland-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "PT-141 / Bremelanotide in Queensland", "boundedAnswer": "PT-141 / Bremelanotide in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-south-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "PT-141 / Bremelanotide in South Australia", "boundedAnswer": "PT-141 / Bremelanotide in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-tasmania-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "PT-141 / Bremelanotide in Tasmania", "boundedAnswer": "PT-141 / Bremelanotide in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-victoria-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "PT-141 / Bremelanotide in Victoria", "boundedAnswer": "PT-141 / Bremelanotide in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-pt-141-western-australia", "compound": "PT-141 / Bremelanotide", "compoundSlug": "pt-141", "compoundAliases": [ "PT 141", "Bremelanotide", "Vyleesi" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a separate FDA-approved medicine record", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "PT-141 / Bremelanotide in Western Australia", "boundedAnswer": "PT-141 / Bremelanotide in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/pt-141", "identitySourceLabel": "Read the current DailyMed drug label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pt-141/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pt-141/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-australian-capital-territory", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "CJC-1295 no DAC in Australian Capital Territory", "boundedAnswer": "CJC-1295 no DAC in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-new-south-wales", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "CJC-1295 no DAC in New South Wales", "boundedAnswer": "CJC-1295 no DAC in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-northern-territory-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "CJC-1295 no DAC in Northern Territory", "boundedAnswer": "CJC-1295 no DAC in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-queensland-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "CJC-1295 no DAC in Queensland", "boundedAnswer": "CJC-1295 no DAC in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-south-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "CJC-1295 no DAC in South Australia", "boundedAnswer": "CJC-1295 no DAC in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-tasmania-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "CJC-1295 no DAC in Tasmania", "boundedAnswer": "CJC-1295 no DAC in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-victoria-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "CJC-1295 no DAC in Victoria", "boundedAnswer": "CJC-1295 no DAC in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-no-dac-western-australia", "compound": "CJC-1295 no DAC", "compoundSlug": "cjc-1295-no-dac", "compoundAliases": [ "Modified GRF 1-29", "Mod GRF 1-29", "CJC 1295 without DAC" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "CJC-1295 no DAC in Western Australia", "boundedAnswer": "CJC-1295 no DAC in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-no-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-no-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-australian-capital-territory", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "CJC-1295 DAC in Australian Capital Territory", "boundedAnswer": "CJC-1295 DAC in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-new-south-wales", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "CJC-1295 DAC in New South Wales", "boundedAnswer": "CJC-1295 DAC in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-northern-territory-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "CJC-1295 DAC in Northern Territory", "boundedAnswer": "CJC-1295 DAC in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-queensland-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "CJC-1295 DAC in Queensland", "boundedAnswer": "CJC-1295 DAC in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-south-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "CJC-1295 DAC in South Australia", "boundedAnswer": "CJC-1295 DAC in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-tasmania-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "CJC-1295 DAC in Tasmania", "boundedAnswer": "CJC-1295 DAC in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-victoria-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "CJC-1295 DAC in Victoria", "boundedAnswer": "CJC-1295 DAC in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-cjc-1295-dac-western-australia", "compound": "CJC-1295 DAC", "compoundSlug": "cjc-1295-dac", "compoundAliases": [ "CJC-1295 with DAC", "CJC 1295 DAC", "DAC:GRF" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "CJC-1295 DAC in Western Australia", "boundedAnswer": "CJC-1295 DAC in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/cjc-1295-dac", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cjc-1295-dac/countries" }, { "recordId": "pl-australia-region-retatrutide-australian-capital-territory", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Retatrutide in Australian Capital Territory", "boundedAnswer": "Retatrutide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-new-south-wales", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Retatrutide in New South Wales", "boundedAnswer": "Retatrutide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-northern-territory-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Retatrutide in Northern Territory", "boundedAnswer": "Retatrutide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-queensland-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Retatrutide in Queensland", "boundedAnswer": "Retatrutide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-south-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Retatrutide in South Australia", "boundedAnswer": "Retatrutide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-tasmania-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Retatrutide in Tasmania", "boundedAnswer": "Retatrutide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-victoria-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Retatrutide in Victoria", "boundedAnswer": "Retatrutide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-retatrutide-western-australia", "compound": "Retatrutide", "compoundSlug": "retatrutide", "compoundAliases": [ "LY3437943", "triple agonist", "reta", "reta peptide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Retatrutide in Western Australia", "boundedAnswer": "Retatrutide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/retatrutide", "identitySourceLabel": "TRIUMPH-1 Phase 3 study - NCT05929066", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05929066", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/retatrutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/retatrutide/countries" }, { "recordId": "pl-australia-region-mazdutide-australian-capital-territory", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Mazdutide in Australian Capital Territory", "boundedAnswer": "Mazdutide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-new-south-wales", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Mazdutide in New South Wales", "boundedAnswer": "Mazdutide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-northern-territory-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Mazdutide in Northern Territory", "boundedAnswer": "Mazdutide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-queensland-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Mazdutide in Queensland", "boundedAnswer": "Mazdutide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-south-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Mazdutide in South Australia", "boundedAnswer": "Mazdutide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-tasmania-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Mazdutide in Tasmania", "boundedAnswer": "Mazdutide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-victoria-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Mazdutide in Victoria", "boundedAnswer": "Mazdutide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-mazdutide-western-australia", "compound": "Mazdutide", "compoundSlug": "mazdutide", "compoundAliases": [ "IBI362", "LY3305677", "GLP-1/glucagon dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Mazdutide in Western Australia", "boundedAnswer": "Mazdutide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/mazdutide", "identitySourceLabel": "GLORY-1 Phase 3 study - NCT05607680", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05607680", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/mazdutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/mazdutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-australian-capital-territory", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Ecnoglutide in Australian Capital Territory", "boundedAnswer": "Ecnoglutide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-new-south-wales", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Ecnoglutide in New South Wales", "boundedAnswer": "Ecnoglutide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-northern-territory-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Ecnoglutide in Northern Territory", "boundedAnswer": "Ecnoglutide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-queensland-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Ecnoglutide in Queensland", "boundedAnswer": "Ecnoglutide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-south-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Ecnoglutide in South Australia", "boundedAnswer": "Ecnoglutide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-tasmania-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Ecnoglutide in Tasmania", "boundedAnswer": "Ecnoglutide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-victoria-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Ecnoglutide in Victoria", "boundedAnswer": "Ecnoglutide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-ecnoglutide-western-australia", "compound": "Ecnoglutide", "compoundSlug": "ecnoglutide", "compoundAliases": [ "XW003", "Sciwind ecnoglutide", "cAMP-biased GLP-1 receptor agonist", "埃诺格鲁肽" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "China-approved medicine and active development program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Ecnoglutide in Western Australia", "boundedAnswer": "Ecnoglutide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/ecnoglutide", "identitySourceLabel": "SLIMMER Phase 3 study - NCT05813795", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05813795", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/ecnoglutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/ecnoglutide/countries" }, { "recordId": "pl-australia-region-enicepatide-australian-capital-territory", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Enicepatide in Australian Capital Territory", "boundedAnswer": "Enicepatide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-new-south-wales", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Enicepatide in New South Wales", "boundedAnswer": "Enicepatide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-northern-territory-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Enicepatide in Northern Territory", "boundedAnswer": "Enicepatide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-queensland-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Enicepatide in Queensland", "boundedAnswer": "Enicepatide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-south-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Enicepatide in South Australia", "boundedAnswer": "Enicepatide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-tasmania-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Enicepatide in Tasmania", "boundedAnswer": "Enicepatide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-victoria-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Enicepatide in Victoria", "boundedAnswer": "Enicepatide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-enicepatide-western-australia", "compound": "Enicepatide", "compoundSlug": "enicepatide", "compoundAliases": [ "CT-388", "RO7795068", "RG6640" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Enicepatide in Western Australia", "boundedAnswer": "Enicepatide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/enicepatide", "identitySourceLabel": "CT388-103 Phase 2 study - NCT06525935", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06525935", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/enicepatide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/enicepatide/countries" }, { "recordId": "pl-australia-region-eloralintide-australian-capital-territory", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Eloralintide in Australian Capital Territory", "boundedAnswer": "Eloralintide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-new-south-wales", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Eloralintide in New South Wales", "boundedAnswer": "Eloralintide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-northern-territory-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Eloralintide in Northern Territory", "boundedAnswer": "Eloralintide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-queensland-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Eloralintide in Queensland", "boundedAnswer": "Eloralintide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-south-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Eloralintide in South Australia", "boundedAnswer": "Eloralintide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-tasmania-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Eloralintide in Tasmania", "boundedAnswer": "Eloralintide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-victoria-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Eloralintide in Victoria", "boundedAnswer": "Eloralintide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-eloralintide-western-australia", "compound": "Eloralintide", "compoundSlug": "eloralintide", "compoundAliases": [ "LY3841136", "eloralintide peptide", "selective amylin receptor agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Eloralintide in Western Australia", "boundedAnswer": "Eloralintide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/eloralintide", "identitySourceLabel": "Eloralintide Phase 2 study - NCT06230523", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06230523", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/eloralintide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/eloralintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-australian-capital-territory", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Cagrilintide in Australian Capital Territory", "boundedAnswer": "Cagrilintide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-new-south-wales", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Cagrilintide in New South Wales", "boundedAnswer": "Cagrilintide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-northern-territory-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Cagrilintide in Northern Territory", "boundedAnswer": "Cagrilintide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-queensland-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Cagrilintide in Queensland", "boundedAnswer": "Cagrilintide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-south-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Cagrilintide in South Australia", "boundedAnswer": "Cagrilintide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-tasmania-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Cagrilintide in Tasmania", "boundedAnswer": "Cagrilintide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-victoria-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Cagrilintide in Victoria", "boundedAnswer": "Cagrilintide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-cagrilintide-western-australia", "compound": "Cagrilintide", "compoundSlug": "cagrilintide", "compoundAliases": [ "AM833", "NNC0174-0833" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Cagrilintide in Western Australia", "boundedAnswer": "Cagrilintide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrilintide", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrilintide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrilintide/countries" }, { "recordId": "pl-australia-region-petrelintide-australian-capital-territory", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Petrelintide in Australian Capital Territory", "boundedAnswer": "Petrelintide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-new-south-wales", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Petrelintide in New South Wales", "boundedAnswer": "Petrelintide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-northern-territory-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Petrelintide in Northern Territory", "boundedAnswer": "Petrelintide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-queensland-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Petrelintide in Queensland", "boundedAnswer": "Petrelintide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-south-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Petrelintide in South Australia", "boundedAnswer": "Petrelintide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-tasmania-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Petrelintide in Tasmania", "boundedAnswer": "Petrelintide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-victoria-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Petrelintide in Victoria", "boundedAnswer": "Petrelintide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-petrelintide-western-australia", "compound": "Petrelintide", "compoundSlug": "petrelintide", "compoundAliases": [ "ZP8396", "long-acting amylin analogue" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Petrelintide in Western Australia", "boundedAnswer": "Petrelintide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/petrelintide", "identitySourceLabel": "ZUPREME-1 Phase 2 study - NCT06662539", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06662539", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/petrelintide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/petrelintide/countries" }, { "recordId": "pl-australia-region-cagrisema-australian-capital-territory", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "CagriSema in Australian Capital Territory", "boundedAnswer": "CagriSema in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-new-south-wales", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "CagriSema in New South Wales", "boundedAnswer": "CagriSema in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-northern-territory-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "CagriSema in Northern Territory", "boundedAnswer": "CagriSema in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-queensland-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "CagriSema in Queensland", "boundedAnswer": "CagriSema in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-south-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "CagriSema in South Australia", "boundedAnswer": "CagriSema in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-tasmania-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "CagriSema in Tasmania", "boundedAnswer": "CagriSema in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-victoria-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "CagriSema in Victoria", "boundedAnswer": "CagriSema in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-cagrisema-western-australia", "compound": "CagriSema", "compoundSlug": "cagrisema", "compoundAliases": [ "cagrilintide + semaglutide", "REDEFINE 1", "REIMAGINE 1-3" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "CagriSema in Western Australia", "boundedAnswer": "CagriSema in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/cagrisema", "identitySourceLabel": "REDEFINE 1 Phase 3 study - NCT05567796", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05567796", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/cagrisema/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/cagrisema/countries" }, { "recordId": "pl-australia-region-maritide-australian-capital-territory", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "MariTide in Australian Capital Territory", "boundedAnswer": "MariTide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-new-south-wales", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "MariTide in New South Wales", "boundedAnswer": "MariTide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-northern-territory-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "MariTide in Northern Territory", "boundedAnswer": "MariTide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-queensland-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "MariTide in Queensland", "boundedAnswer": "MariTide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-south-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "MariTide in South Australia", "boundedAnswer": "MariTide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-tasmania-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "MariTide in Tasmania", "boundedAnswer": "MariTide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-victoria-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "MariTide in Victoria", "boundedAnswer": "MariTide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-maritide-western-australia", "compound": "MariTide", "compoundSlug": "maritide", "compoundAliases": [ "maridebart cafraglutide", "AMG 133" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "MariTide in Western Australia", "boundedAnswer": "MariTide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/maritide", "identitySourceLabel": "Phase 2 dose-ranging study - NCT05669599", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05669599", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/maritide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/maritide/countries" }, { "recordId": "pl-australia-region-survodutide-australian-capital-territory", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Survodutide in Australian Capital Territory", "boundedAnswer": "Survodutide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-new-south-wales", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Survodutide in New South Wales", "boundedAnswer": "Survodutide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-northern-territory-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Survodutide in Northern Territory", "boundedAnswer": "Survodutide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-queensland-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Survodutide in Queensland", "boundedAnswer": "Survodutide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-south-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Survodutide in South Australia", "boundedAnswer": "Survodutide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-tasmania-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Survodutide in Tasmania", "boundedAnswer": "Survodutide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-victoria-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Survodutide in Victoria", "boundedAnswer": "Survodutide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-survodutide-western-australia", "compound": "Survodutide", "compoundSlug": "survodutide", "compoundAliases": [ "BI 456906", "glucagon/GLP-1 dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Survodutide in Western Australia", "boundedAnswer": "Survodutide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/survodutide", "identitySourceLabel": "SYNCHRONIZE-1 Phase 3 study - NCT06066515", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06066515", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/survodutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/survodutide/countries" }, { "recordId": "pl-australia-region-vk2735-australian-capital-territory", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "VK2735 in Australian Capital Territory", "boundedAnswer": "VK2735 in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-new-south-wales", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "VK2735 in New South Wales", "boundedAnswer": "VK2735 in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-northern-territory-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "VK2735 in Northern Territory", "boundedAnswer": "VK2735 in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-queensland-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "VK2735 in Queensland", "boundedAnswer": "VK2735 in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-south-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "VK2735 in South Australia", "boundedAnswer": "VK2735 in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-tasmania-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "VK2735 in Tasmania", "boundedAnswer": "VK2735 in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-victoria-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "VK2735 in Victoria", "boundedAnswer": "VK2735 in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-vk2735-western-australia", "compound": "VK2735", "compoundSlug": "vk2735", "compoundAliases": [ "Viking VK2735", "oral VK2735", "GLP-1/GIP dual agonist" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "VK2735 in Western Australia", "boundedAnswer": "VK2735 in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/vk2735", "identitySourceLabel": "VENTURE injectable Phase 2 study - NCT06068946", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT06068946", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vk2735/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vk2735/countries" }, { "recordId": "pl-australia-region-pemvidutide-australian-capital-territory", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Pemvidutide in Australian Capital Territory", "boundedAnswer": "Pemvidutide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-new-south-wales", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Pemvidutide in New South Wales", "boundedAnswer": "Pemvidutide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-northern-territory-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Pemvidutide in Northern Territory", "boundedAnswer": "Pemvidutide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-queensland-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Pemvidutide in Queensland", "boundedAnswer": "Pemvidutide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-south-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Pemvidutide in South Australia", "boundedAnswer": "Pemvidutide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-tasmania-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Pemvidutide in Tasmania", "boundedAnswer": "Pemvidutide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-victoria-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Pemvidutide in Victoria", "boundedAnswer": "Pemvidutide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-pemvidutide-western-australia", "compound": "Pemvidutide", "compoundSlug": "pemvidutide", "compoundAliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist", "Altimmune pemvidutide" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Pemvidutide in Western Australia", "boundedAnswer": "Pemvidutide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/pemvidutide", "identitySourceLabel": "IMPACT Phase 2b MASH study - NCT05989711", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT05989711", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/pemvidutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/pemvidutide/countries" }, { "recordId": "pl-australia-region-amycretin-australian-capital-territory", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Amycretin / Zenagamtide in Australian Capital Territory", "boundedAnswer": "Amycretin / Zenagamtide in Australian Capital Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-new-south-wales", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Amycretin / Zenagamtide in New South Wales", "boundedAnswer": "Amycretin / Zenagamtide in New South Wales refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-northern-territory-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Amycretin / Zenagamtide in Northern Territory", "boundedAnswer": "Amycretin / Zenagamtide in Northern Territory refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-queensland-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Amycretin / Zenagamtide in Queensland", "boundedAnswer": "Amycretin / Zenagamtide in Queensland refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-south-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Amycretin / Zenagamtide in South Australia", "boundedAnswer": "Amycretin / Zenagamtide in South Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-tasmania-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Amycretin / Zenagamtide in Tasmania", "boundedAnswer": "Amycretin / Zenagamtide in Tasmania refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-victoria-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Amycretin / Zenagamtide in Victoria", "boundedAnswer": "Amycretin / Zenagamtide in Victoria refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-amycretin-western-australia", "compound": "Amycretin / Zenagamtide", "compoundSlug": "amycretin", "compoundAliases": [ "amycretin", "NNC0487-0111", "AMAZE 7" ], "evidenceLane": "Clinical pipeline profile", "identityStatus": "Investigational clinical program", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Amycretin / Zenagamtide in Western Australia", "boundedAnswer": "Amycretin / Zenagamtide in Western Australia refers first to an investigational clinical program, not an approved Australian product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, manufacturing controls, or regulatory status. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/pipeline/amycretin", "identitySourceLabel": "AMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414", "identitySourcePublisher": "ClinicalTrials.gov", "identitySourceUrl": "https://clinicaltrials.gov/study/NCT07668414", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/amycretin/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/amycretin/countries" }, { "recordId": "pl-australia-region-tirzepatide-australian-capital-territory", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Tirzepatide in Australian Capital Territory", "boundedAnswer": "Tirzepatide in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-new-south-wales", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Tirzepatide in New South Wales", "boundedAnswer": "Tirzepatide in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-northern-territory-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Tirzepatide in Northern Territory", "boundedAnswer": "Tirzepatide in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-queensland-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Tirzepatide in Queensland", "boundedAnswer": "Tirzepatide in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-south-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Tirzepatide in South Australia", "boundedAnswer": "Tirzepatide in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-tasmania-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Tirzepatide in Tasmania", "boundedAnswer": "Tirzepatide in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-victoria-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Tirzepatide in Victoria", "boundedAnswer": "Tirzepatide in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-tirzepatide-western-australia", "compound": "Tirzepatide", "compoundSlug": "tirzepatide", "compoundAliases": [ "tirzepatide", "Zepbound", "LY3298176", "NDA 217806", "GIP and GLP-1 receptor agonist" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "US FDA medicine reference", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Tirzepatide in Western Australia", "boundedAnswer": "Tirzepatide in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/zepbound", "identitySourceLabel": "Current ZEPBOUND prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/tirzepatide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/tirzepatide/countries" }, { "recordId": "pl-australia-region-orforglipron-australian-capital-territory", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Orforglipron / Foundayo in Australian Capital Territory", "boundedAnswer": "Orforglipron / Foundayo in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-new-south-wales", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Orforglipron / Foundayo in New South Wales", "boundedAnswer": "Orforglipron / Foundayo in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-northern-territory-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Orforglipron / Foundayo in Northern Territory", "boundedAnswer": "Orforglipron / Foundayo in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-queensland-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Orforglipron / Foundayo in Queensland", "boundedAnswer": "Orforglipron / Foundayo in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-south-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Orforglipron / Foundayo in South Australia", "boundedAnswer": "Orforglipron / Foundayo in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-tasmania-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Orforglipron / Foundayo in Tasmania", "boundedAnswer": "Orforglipron / Foundayo in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-victoria-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Orforglipron / Foundayo in Victoria", "boundedAnswer": "Orforglipron / Foundayo in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-orforglipron-western-australia", "compound": "Orforglipron / Foundayo", "compoundSlug": "orforglipron", "compoundAliases": [ "orforglipron", "Foundayo", "LY3502970", "NDA 220934", "oral GLP-1", "nonpeptide GLP-1", "non-peptide GLP-1", "weight loss pill" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with country-specific status elsewhere", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Orforglipron / Foundayo in Western Australia", "boundedAnswer": "Orforglipron / Foundayo in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/foundayo", "identitySourceLabel": "Current FOUNDAYO prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/orforglipron/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/orforglipron/countries" }, { "recordId": "pl-australia-region-semaglutide-australian-capital-territory", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Semaglutide in Australian Capital Territory", "boundedAnswer": "Semaglutide in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-new-south-wales", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Semaglutide in New South Wales", "boundedAnswer": "Semaglutide in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-northern-territory-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Semaglutide in Northern Territory", "boundedAnswer": "Semaglutide in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-queensland-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Semaglutide in Queensland", "boundedAnswer": "Semaglutide in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-south-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Semaglutide in South Australia", "boundedAnswer": "Semaglutide in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-tasmania-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Semaglutide in Tasmania", "boundedAnswer": "Semaglutide in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-victoria-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Semaglutide in Victoria", "boundedAnswer": "Semaglutide in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-semaglutide-western-australia", "compound": "Semaglutide", "compoundSlug": "semaglutide", "compoundAliases": [ "semaglutide", "Wegovy", "NDA 215256", "GLP-1 receptor agonist", "semaglutide injection", "semaglutide tablets", "oral Wegovy", "Wegovy pill", "sémaglutide", "semaglutida", "Semaglutid", "司美格鲁肽", "semaglutyd", "semaglutid", "Ozempic by country", "Rybelsus by country" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific approved medicine records in multiple jurisdictions", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Semaglutide in Western Australia", "boundedAnswer": "Semaglutide in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/wegovy", "identitySourceLabel": "Current WEGOVY prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/semaglutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/semaglutide/countries" }, { "recordId": "pl-australia-region-dsip-australian-capital-territory", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "DSIP / Emideltide in Australian Capital Territory", "boundedAnswer": "DSIP / Emideltide in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-new-south-wales", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "DSIP / Emideltide in New South Wales", "boundedAnswer": "DSIP / Emideltide in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-northern-territory-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "DSIP / Emideltide in Northern Territory", "boundedAnswer": "DSIP / Emideltide in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-queensland-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "DSIP / Emideltide in Queensland", "boundedAnswer": "DSIP / Emideltide in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-south-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "DSIP / Emideltide in South Australia", "boundedAnswer": "DSIP / Emideltide in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-tasmania-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "DSIP / Emideltide in Tasmania", "boundedAnswer": "DSIP / Emideltide in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-victoria-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "DSIP / Emideltide in Victoria", "boundedAnswer": "DSIP / Emideltide in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-dsip-western-australia", "compound": "DSIP / Emideltide", "compoundSlug": "dsip", "compoundAliases": [ "Delta sleep-inducing peptide", "Emideltide", "DSIP nonapeptide", "delta sleep-inducing peptide", "delta sleep inducing peptide", "DSIP peptide" ], "evidenceLane": "Research price board", "identityStatus": "FDA-flagged unapproved research-market peptide identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "DSIP / Emideltide in Western Australia", "boundedAnswer": "DSIP / Emideltide in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/dsip", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/dsip/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/dsip/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-australian-capital-territory", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "IGF-1 LR3 in Australian Capital Territory", "boundedAnswer": "IGF-1 LR3 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-new-south-wales", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "IGF-1 LR3 in New South Wales", "boundedAnswer": "IGF-1 LR3 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-northern-territory-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "IGF-1 LR3 in Northern Territory", "boundedAnswer": "IGF-1 LR3 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-queensland-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "IGF-1 LR3 in Queensland", "boundedAnswer": "IGF-1 LR3 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-south-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "IGF-1 LR3 in South Australia", "boundedAnswer": "IGF-1 LR3 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-tasmania-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "IGF-1 LR3 in Tasmania", "boundedAnswer": "IGF-1 LR3 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-victoria-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "IGF-1 LR3 in Victoria", "boundedAnswer": "IGF-1 LR3 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-igf-1-lr3-western-australia", "compound": "IGF-1 LR3", "compoundSlug": "igf-1-lr3", "compoundAliases": [ "Long R3 IGF-1", "Insulin-like growth factor long chain R3", "100 mcg IGF-1 LR3", "IGF1 LR3", "IGF-1 long R3" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "IGF-1 LR3 in Western Australia", "boundedAnswer": "IGF-1 LR3 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/igf-1-lr3", "identitySourceLabel": "Read the PubChem substance record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/substance/381123731", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/igf-1-lr3/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/igf-1-lr3/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-australian-capital-territory", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Kisspeptin-10 / KP-10 in Australian Capital Territory", "boundedAnswer": "Kisspeptin-10 / KP-10 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-new-south-wales", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Kisspeptin-10 / KP-10 in New South Wales", "boundedAnswer": "Kisspeptin-10 / KP-10 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-northern-territory-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Kisspeptin-10 / KP-10 in Northern Territory", "boundedAnswer": "Kisspeptin-10 / KP-10 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-queensland-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Kisspeptin-10 / KP-10 in Queensland", "boundedAnswer": "Kisspeptin-10 / KP-10 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-south-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Kisspeptin-10 / KP-10 in South Australia", "boundedAnswer": "Kisspeptin-10 / KP-10 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-tasmania-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Kisspeptin-10 / KP-10 in Tasmania", "boundedAnswer": "Kisspeptin-10 / KP-10 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-victoria-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Kisspeptin-10 / KP-10 in Victoria", "boundedAnswer": "Kisspeptin-10 / KP-10 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-kisspeptin-10-western-australia", "compound": "Kisspeptin-10 / KP-10", "compoundSlug": "kisspeptin-10", "compoundAliases": [ "Kisspeptin 10", "Kp-10", "Metastin fragment", "KISS1 decapeptide", "kisspeptin 10", "KP-10", "Kp10" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Kisspeptin-10 / KP-10 in Western Australia", "boundedAnswer": "Kisspeptin-10 / KP-10 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/kisspeptin-10", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/25240297", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/kisspeptin-10/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/kisspeptin-10/countries" }, { "recordId": "pl-australia-region-melanotan-i-australian-capital-territory", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Melanotan I in Australian Capital Territory", "boundedAnswer": "Melanotan I in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-new-south-wales", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Melanotan I in New South Wales", "boundedAnswer": "Melanotan I in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-northern-territory-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Melanotan I in Northern Territory", "boundedAnswer": "Melanotan I in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-queensland-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Melanotan I in Queensland", "boundedAnswer": "Melanotan I in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-south-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Melanotan I in South Australia", "boundedAnswer": "Melanotan I in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-tasmania-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Melanotan I in Tasmania", "boundedAnswer": "Melanotan I in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-victoria-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Melanotan I in Victoria", "boundedAnswer": "Melanotan I in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-melanotan-i-western-australia", "compound": "Melanotan I", "compoundSlug": "melanotan-i", "compoundAliases": [ "MT-I", "MT1", "Afamelanotide", "Melanotan 1" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity separated from SCENESSE", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Melanotan I in Western Australia", "boundedAnswer": "Melanotan I in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/melanotan-i", "identitySourceLabel": "Read the current SCENESSE label", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/melanotan-i/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/melanotan-i/countries" }, { "recordId": "pl-australia-region-nad-plus-australian-capital-territory", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "NAD+ in Australian Capital Territory", "boundedAnswer": "NAD+ in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-new-south-wales", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "NAD+ in New South Wales", "boundedAnswer": "NAD+ in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-northern-territory-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "NAD+ in Northern Territory", "boundedAnswer": "NAD+ in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-queensland-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "NAD+ in Queensland", "boundedAnswer": "NAD+ in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-south-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "NAD+ in South Australia", "boundedAnswer": "NAD+ in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-tasmania-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "NAD+ in Tasmania", "boundedAnswer": "NAD+ in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-victoria-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "NAD+ in Victoria", "boundedAnswer": "NAD+ in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-nad-plus-western-australia", "compound": "NAD+", "compoundSlug": "nad-plus", "compoundAliases": [ "Nicotinamide adenine dinucleotide", "NAD plus", "nicotinamide adenine dinucleotide", "NAD peptide" ], "evidenceLane": "Research price board", "identityStatus": "US research-market non-peptide coenzyme identity", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "NAD+ in Western Australia", "boundedAnswer": "NAD+ in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/nad-plus", "identitySourceLabel": "Read the PubChem compound record", "identitySourcePublisher": "National Library of Medicine, PubChem", "identitySourceUrl": "https://pubchem.ncbi.nlm.nih.gov/compound/Nadide-_JAN_USAN_INN", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/nad-plus/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/nad-plus/countries" }, { "recordId": "pl-australia-region-sermorelin-australian-capital-territory", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Sermorelin in Australian Capital Territory", "boundedAnswer": "Sermorelin in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-new-south-wales", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Sermorelin in New South Wales", "boundedAnswer": "Sermorelin in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-northern-territory-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Sermorelin in Northern Territory", "boundedAnswer": "Sermorelin in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-queensland-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Sermorelin in Queensland", "boundedAnswer": "Sermorelin in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-south-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Sermorelin in South Australia", "boundedAnswer": "Sermorelin in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-tasmania-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Sermorelin in Tasmania", "boundedAnswer": "Sermorelin in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-victoria-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Sermorelin in Victoria", "boundedAnswer": "Sermorelin in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-sermorelin-western-australia", "compound": "Sermorelin", "compoundSlug": "sermorelin", "compoundAliases": [ "GHRH 1-29", "Sermorelin acetate", "Geref" ], "evidenceLane": "Research price board", "identityStatus": "US research-market identity with a withdrawn historical medicine record", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Sermorelin in Western Australia", "boundedAnswer": "Sermorelin in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/sermorelin", "identitySourceLabel": "Read the FDA orphan-drug record", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/sermorelin/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/sermorelin/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-australian-capital-territory", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Thymosin Alpha-1 in Australian Capital Territory", "boundedAnswer": "Thymosin Alpha-1 in Australian Capital Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-new-south-wales", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Thymosin Alpha-1 in New South Wales", "boundedAnswer": "Thymosin Alpha-1 in New South Wales begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-northern-territory-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Thymosin Alpha-1 in Northern Territory", "boundedAnswer": "Thymosin Alpha-1 in Northern Territory begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-queensland-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Thymosin Alpha-1 in Queensland", "boundedAnswer": "Thymosin Alpha-1 in Queensland begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-south-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Thymosin Alpha-1 in South Australia", "boundedAnswer": "Thymosin Alpha-1 in South Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-tasmania-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Thymosin Alpha-1 in Tasmania", "boundedAnswer": "Thymosin Alpha-1 in Tasmania begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-victoria-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Thymosin Alpha-1 in Victoria", "boundedAnswer": "Thymosin Alpha-1 in Victoria begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-thymosin-alpha-1-western-australia", "compound": "Thymosin Alpha-1", "compoundSlug": "thymosin-alpha-1", "compoundAliases": [ "Thymalfasin", "TA1", "Thymosin alpha 1", "thymosin alpha 1", "TA-1", "Tα1", "thymalfasin" ], "evidenceLane": "Research price board", "identityStatus": "No FDA-approved US product; exact foreign prescription products exist", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Thymosin Alpha-1 in Western Australia", "boundedAnswer": "Thymosin Alpha-1 in Western Australia begins with a research-market identity, not a finding that a same-name product is included in the ARTG, lawfully supplied, locally available, independently tested, or appropriate for use in Australia. A research-use disclaimer cannot resolve those questions by itself. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/products/thymosin-alpha-1", "identitySourceLabel": "Read the FDA source", "identitySourcePublisher": "U.S. Food and Drug Administration", "identitySourceUrl": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/thymosin-alpha-1/countries" }, { "recordId": "pl-australia-region-egrifta-wr-australian-capital-territory", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "EGRIFTA WR in Australian Capital Territory", "boundedAnswer": "EGRIFTA WR in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-new-south-wales", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "EGRIFTA WR in New South Wales", "boundedAnswer": "EGRIFTA WR in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-northern-territory-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "EGRIFTA WR in Northern Territory", "boundedAnswer": "EGRIFTA WR in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-queensland-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "EGRIFTA WR in Queensland", "boundedAnswer": "EGRIFTA WR in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-south-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "EGRIFTA WR in South Australia", "boundedAnswer": "EGRIFTA WR in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-tasmania-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "EGRIFTA WR in Tasmania", "boundedAnswer": "EGRIFTA WR in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-victoria-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "EGRIFTA WR in Victoria", "boundedAnswer": "EGRIFTA WR in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-egrifta-wr-western-australia", "compound": "EGRIFTA WR", "compoundSlug": "egrifta-wr", "compoundAliases": [ "tesamorelin", "Egrifta WR", "Egrifta SV", "TH9507", "BLA 022505", "GHRF analog", "Egrifta", "tesamorelin medicine" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "FDA-approved US medicine with a withdrawn EU application", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "EGRIFTA WR in Western Australia", "boundedAnswer": "EGRIFTA WR in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/egrifta-wr", "identitySourceLabel": "Current EGRIFTA WR prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/egrifta-wr/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/egrifta-wr/countries" }, { "recordId": "pl-australia-region-liraglutide-australian-capital-territory", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "Liraglutide in Australian Capital Territory", "boundedAnswer": "Liraglutide in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-new-south-wales", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "Liraglutide in New South Wales", "boundedAnswer": "Liraglutide in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-northern-territory-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "Liraglutide in Northern Territory", "boundedAnswer": "Liraglutide in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-queensland-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "Liraglutide in Queensland", "boundedAnswer": "Liraglutide in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-south-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "Liraglutide in South Australia", "boundedAnswer": "Liraglutide in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-tasmania-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "Liraglutide in Tasmania", "boundedAnswer": "Liraglutide in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-victoria-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "Liraglutide in Victoria", "boundedAnswer": "Liraglutide in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-liraglutide-western-australia", "compound": "Liraglutide", "compoundSlug": "liraglutide", "compoundAliases": [ "liraglutide", "Saxenda", "NN2211", "NDA 206321", "GLP-1 receptor agonist", "Saxenda by country", "liraglutida", "Liraglutid" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "Liraglutide in Western Australia", "boundedAnswer": "Liraglutide in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/saxenda", "identitySourceLabel": "Current SAXENDA prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/liraglutide/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/liraglutide/countries" }, { "recordId": "pl-australia-region-scenesse-australian-capital-territory", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "SCENESSE in Australian Capital Territory", "boundedAnswer": "SCENESSE in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-new-south-wales", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "SCENESSE in New South Wales", "boundedAnswer": "SCENESSE in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-northern-territory-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "SCENESSE in Northern Territory", "boundedAnswer": "SCENESSE in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-queensland-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "SCENESSE in Queensland", "boundedAnswer": "SCENESSE in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-south-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "SCENESSE in South Australia", "boundedAnswer": "SCENESSE in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-tasmania-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "SCENESSE in Tasmania", "boundedAnswer": "SCENESSE in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-victoria-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "SCENESSE in Victoria", "boundedAnswer": "SCENESSE in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-scenesse-western-australia", "compound": "SCENESSE", "compoundSlug": "scenesse", "compoundAliases": [ "afamelanotide", "Scenesse", "CUV1647", "NDA 210797", "alpha-MSH analog", "Scenesse by country", "afamelanotide implant", "afamelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA and EU medicine records", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "SCENESSE in Western Australia", "boundedAnswer": "SCENESSE in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/scenesse", "identitySourceLabel": "Current SCENESSE prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/scenesse/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/scenesse/countries" }, { "recordId": "pl-australia-region-vyleesi-australian-capital-territory", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Australian Capital Territory", "jurisdictionSlug": "australian-capital-territory", "searchQuery": "VYLEESI in Australian Capital Territory", "boundedAnswer": "VYLEESI in Australian Capital Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Australian Capital Territory, open Pharmaceutical Services from ACT Government and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmaceutical Services", "jurisdictionRecordPublisher": "ACT Government", "jurisdictionRecordUrl": "https://www.act.gov.au/directorates-and-agencies/health-and-community-services-directorate/pharmaceutical-services", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#australian-capital-territory", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/australian-capital-territory", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-new-south-wales", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "New South Wales", "jurisdictionSlug": "new-south-wales", "searchQuery": "VYLEESI in New South Wales", "boundedAnswer": "VYLEESI in New South Wales begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving New South Wales, open Register of Pharmacies from Pharmacy Council of New South Wales and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Register of Pharmacies", "jurisdictionRecordPublisher": "Pharmacy Council of New South Wales", "jurisdictionRecordUrl": "https://www.pharmacycouncil.nsw.gov.au/registered-pharmacies", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#new-south-wales", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/new-south-wales", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-northern-territory-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Northern Territory", "jurisdictionSlug": "northern-territory-australia", "searchQuery": "VYLEESI in Northern Territory", "boundedAnswer": "VYLEESI in Northern Territory begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Northern Territory, open Medicines and poisons from Northern Territory Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Medicines and poisons", "jurisdictionRecordPublisher": "Northern Territory Health", "jurisdictionRecordUrl": "https://health.nt.gov.au/professionals/medicines-and-poisons-control2", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#northern-territory-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/northern-territory-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-queensland-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Queensland", "jurisdictionSlug": "queensland-australia", "searchQuery": "VYLEESI in Queensland", "boundedAnswer": "VYLEESI in Queensland begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Queensland, open Retail sale of medicines from Queensland Health and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Retail sale of medicines", "jurisdictionRecordPublisher": "Queensland Health", "jurisdictionRecordUrl": "https://www.health.qld.gov.au/system-governance/licences/medicines-poisons/medicines/licensing/retail-sale", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#queensland-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/queensland-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-south-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "South Australia", "jurisdictionSlug": "south-australia", "searchQuery": "VYLEESI in South Australia", "boundedAnswer": "VYLEESI in South Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving South Australia, open Pharmacy premises regulation from Pharmacy Regulation Authority South Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmacy premises regulation", "jurisdictionRecordPublisher": "Pharmacy Regulation Authority South Australia", "jurisdictionRecordUrl": "https://www.pharmacyauthority.sa.gov.au/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#south-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/south-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-tasmania-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Tasmania", "jurisdictionSlug": "tasmania-australia", "searchQuery": "VYLEESI in Tasmania", "boundedAnswer": "VYLEESI in Tasmania begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Tasmania, open Pharmacy premises guidance from Tasmanian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Pharmacy premises guidance", "jurisdictionRecordPublisher": "Tasmanian Pharmacy Authority", "jurisdictionRecordUrl": "https://www.health.tas.gov.au/professionals/tasmanian-pharmacy-authority", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#tasmania-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/tasmania-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-victoria-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Victoria", "jurisdictionSlug": "victoria-australia", "searchQuery": "VYLEESI in Victoria", "boundedAnswer": "VYLEESI in Victoria begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Victoria, open Public register from Victorian Pharmacy Authority and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Public register", "jurisdictionRecordPublisher": "Victorian Pharmacy Authority", "jurisdictionRecordUrl": "https://pharmacy.vic.gov.au/register-search/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#victoria-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/victoria-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" }, { "recordId": "pl-australia-region-vyleesi-western-australia", "compound": "VYLEESI", "compoundSlug": "vyleesi", "compoundAliases": [ "bremelanotide", "Vyleesi", "PT-141", "NDA 210557", "melanocortin receptor agonist", "Vyleesi by country", "bremelanotide medicine", "bremelanotida" ], "evidenceLane": "FDA-approved medicine", "identityStatus": "Product-specific FDA-approved US medicine record", "jurisdiction": "Western Australia", "jurisdictionSlug": "western-australia", "searchQuery": "VYLEESI in Western Australia", "boundedAnswer": "VYLEESI in Western Australia begins with a medicine identity, but Australian authorization belongs to an exact therapeutic good, sponsor, presentation, route, ARTG record, and regulated supply path. A shared ingredient or brand reference does not transfer that record to every listing. For a pharmacy, clinic, practitioner, importer, or seller claim involving Western Australia, open Premises Register from Pharmacy Registration Board of Western Australia and match the business, premises, licence, registration, supply category, and current status. Then search the exact product and sponsor separately in the Australian Register of Therapeutic Goods and check the practitioner in Ahpra when relevant. A local record does not authorize a product, and an ARTG record does not validate a different seller, parcel, or service.", "reviewedDate": "2026-07-20", "identityRecordUrl": "https://peptidelocal.com/medicines/vyleesi", "identitySourceLabel": "Current VYLEESI prescribing information", "identitySourcePublisher": "National Library of Medicine, DailyMed", "identitySourceUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "jurisdictionRecordLabel": "Premises Register", "jurisdictionRecordPublisher": "Pharmacy Registration Board of Western Australia", "jurisdictionRecordUrl": "https://pharmacyboardwa.com.au/premises-register/", "productRecordLabel": "Searching the Australian Register of Therapeutic Goods", "productRecordPublisher": "Therapeutic Goods Administration", "productRecordUrl": "https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg", "canonicalAtlasUrl": "https://peptidelocal.com/peptides/vyleesi/australia-states#western-australia", "jurisdictionGuideUrl": "https://peptidelocal.com/locations/western-australia", "countryMapUrl": "https://peptidelocal.com/peptides/vyleesi/countries" } ] }